Fluvoxamine treatment of mixed anxiety and depression

Evidence for serotonergically mediated anxiolysis

Jeffrey L. Rausch, Henry McCager Hobby, Nitin Sudhakar Shendarkar, Maria E. Johnson, Junqing Li

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Although increasing evidence suggests that selective serotonin reuptake inhibitor (SSRI) treatment may be effective for anxiety in addition to depression, SSRI anxiolysis has not been definitively related to the inhibition of serotonin (5-HT) transport. The gene that encodes for the human serotonin transporter (5-HTT) expresses its protein in neurons and in blood platelets, and both tissues respond to transport inhibition similarly in response to SSRI treatment. This study examined the relationship between the change in the 5-HTT's apparent affinity for 5-HT and the anxiolytic response in a group of 18 fluvoxamine-treated patients meeting Structured Clinical Interview for DSM-IV criteria for both generalized anxiety disorder and major depression. Significant decreases were found in both Hamilton anxiety and Hamilton depression scores over a 2-month treatment period. Robust increases were found in the apparent affinity constant (Km) for platelet 5-HT transport with treatment, and the increases covaried significantly with the decrease in anxiety (F = 4.97,p < 0.03). The pretreatment 5HTT Km significantly correlated with the improvement in depression scores (r = 0.53,p < 0.03), consistent with the Hypothesis of Initial Conditions. These results suggest that the therapeutic effect of SSRI treatment can be linked to the magnitude and time-course of 5-HT transport inhibition effected with fluvoxamine, a drug that seems to have an antianxiety effect of the same magnitude as its effect on depression.

Original languageEnglish (US)
Pages (from-to)139-142
Number of pages4
JournalJournal of Clinical Psychopharmacology
Volume21
Issue number2
DOIs
StatePublished - Mar 28 2001

Fingerprint

Fluvoxamine
Serotonin Uptake Inhibitors
Serotonin
Anxiety
Depression
Anti-Anxiety Agents
Blood Platelets
Therapeutics
Serotonin Plasma Membrane Transport Proteins
Therapeutic Uses
Anxiety Disorders
Diagnostic and Statistical Manual of Mental Disorders
Interviews
Neurons
Pharmaceutical Preparations
Genes
Inhibition (Psychology)
Proteins

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Fluvoxamine treatment of mixed anxiety and depression : Evidence for serotonergically mediated anxiolysis. / Rausch, Jeffrey L.; Hobby, Henry McCager; Shendarkar, Nitin Sudhakar; Johnson, Maria E.; Li, Junqing.

In: Journal of Clinical Psychopharmacology, Vol. 21, No. 2, 28.03.2001, p. 139-142.

Research output: Contribution to journalArticle

Rausch, Jeffrey L. ; Hobby, Henry McCager ; Shendarkar, Nitin Sudhakar ; Johnson, Maria E. ; Li, Junqing. / Fluvoxamine treatment of mixed anxiety and depression : Evidence for serotonergically mediated anxiolysis. In: Journal of Clinical Psychopharmacology. 2001 ; Vol. 21, No. 2. pp. 139-142.
@article{57ebd1bc2d9a4e93bb55f512b36ad963,
title = "Fluvoxamine treatment of mixed anxiety and depression: Evidence for serotonergically mediated anxiolysis",
abstract = "Although increasing evidence suggests that selective serotonin reuptake inhibitor (SSRI) treatment may be effective for anxiety in addition to depression, SSRI anxiolysis has not been definitively related to the inhibition of serotonin (5-HT) transport. The gene that encodes for the human serotonin transporter (5-HTT) expresses its protein in neurons and in blood platelets, and both tissues respond to transport inhibition similarly in response to SSRI treatment. This study examined the relationship between the change in the 5-HTT's apparent affinity for 5-HT and the anxiolytic response in a group of 18 fluvoxamine-treated patients meeting Structured Clinical Interview for DSM-IV criteria for both generalized anxiety disorder and major depression. Significant decreases were found in both Hamilton anxiety and Hamilton depression scores over a 2-month treatment period. Robust increases were found in the apparent affinity constant (Km) for platelet 5-HT transport with treatment, and the increases covaried significantly with the decrease in anxiety (F = 4.97,p < 0.03). The pretreatment 5HTT Km significantly correlated with the improvement in depression scores (r = 0.53,p < 0.03), consistent with the Hypothesis of Initial Conditions. These results suggest that the therapeutic effect of SSRI treatment can be linked to the magnitude and time-course of 5-HT transport inhibition effected with fluvoxamine, a drug that seems to have an antianxiety effect of the same magnitude as its effect on depression.",
author = "Rausch, {Jeffrey L.} and Hobby, {Henry McCager} and Shendarkar, {Nitin Sudhakar} and Johnson, {Maria E.} and Junqing Li",
year = "2001",
month = "3",
day = "28",
doi = "10.1097/00004714-200104000-00004",
language = "English (US)",
volume = "21",
pages = "139--142",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Fluvoxamine treatment of mixed anxiety and depression

T2 - Evidence for serotonergically mediated anxiolysis

AU - Rausch, Jeffrey L.

AU - Hobby, Henry McCager

AU - Shendarkar, Nitin Sudhakar

AU - Johnson, Maria E.

AU - Li, Junqing

PY - 2001/3/28

Y1 - 2001/3/28

N2 - Although increasing evidence suggests that selective serotonin reuptake inhibitor (SSRI) treatment may be effective for anxiety in addition to depression, SSRI anxiolysis has not been definitively related to the inhibition of serotonin (5-HT) transport. The gene that encodes for the human serotonin transporter (5-HTT) expresses its protein in neurons and in blood platelets, and both tissues respond to transport inhibition similarly in response to SSRI treatment. This study examined the relationship between the change in the 5-HTT's apparent affinity for 5-HT and the anxiolytic response in a group of 18 fluvoxamine-treated patients meeting Structured Clinical Interview for DSM-IV criteria for both generalized anxiety disorder and major depression. Significant decreases were found in both Hamilton anxiety and Hamilton depression scores over a 2-month treatment period. Robust increases were found in the apparent affinity constant (Km) for platelet 5-HT transport with treatment, and the increases covaried significantly with the decrease in anxiety (F = 4.97,p < 0.03). The pretreatment 5HTT Km significantly correlated with the improvement in depression scores (r = 0.53,p < 0.03), consistent with the Hypothesis of Initial Conditions. These results suggest that the therapeutic effect of SSRI treatment can be linked to the magnitude and time-course of 5-HT transport inhibition effected with fluvoxamine, a drug that seems to have an antianxiety effect of the same magnitude as its effect on depression.

AB - Although increasing evidence suggests that selective serotonin reuptake inhibitor (SSRI) treatment may be effective for anxiety in addition to depression, SSRI anxiolysis has not been definitively related to the inhibition of serotonin (5-HT) transport. The gene that encodes for the human serotonin transporter (5-HTT) expresses its protein in neurons and in blood platelets, and both tissues respond to transport inhibition similarly in response to SSRI treatment. This study examined the relationship between the change in the 5-HTT's apparent affinity for 5-HT and the anxiolytic response in a group of 18 fluvoxamine-treated patients meeting Structured Clinical Interview for DSM-IV criteria for both generalized anxiety disorder and major depression. Significant decreases were found in both Hamilton anxiety and Hamilton depression scores over a 2-month treatment period. Robust increases were found in the apparent affinity constant (Km) for platelet 5-HT transport with treatment, and the increases covaried significantly with the decrease in anxiety (F = 4.97,p < 0.03). The pretreatment 5HTT Km significantly correlated with the improvement in depression scores (r = 0.53,p < 0.03), consistent with the Hypothesis of Initial Conditions. These results suggest that the therapeutic effect of SSRI treatment can be linked to the magnitude and time-course of 5-HT transport inhibition effected with fluvoxamine, a drug that seems to have an antianxiety effect of the same magnitude as its effect on depression.

UR - http://www.scopus.com/inward/record.url?scp=0035100176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035100176&partnerID=8YFLogxK

U2 - 10.1097/00004714-200104000-00004

DO - 10.1097/00004714-200104000-00004

M3 - Article

VL - 21

SP - 139

EP - 142

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 2

ER -